Investor Relations

About Natera

Natera™ is a global leader in cell-free DNA (cfDNA) testing with a focus on women’s health, oncology, and organ health.

 

Our cutting-edge cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and AI, allowing detection down to a single molecule in a tube of blood. We’ve leveraged this platform to develop the most accurate non-invasive prenatal test on the market (Panorama™), the first tumor-specific assay for truly individualized cancer care (Signatera™), and best-in-class rejection assessment for kidney transplantation (Prospera™), among other transformative cfDNA tests.

 

Natera has performed more than 3 million cfDNA tests in its laboratories, more than any other, studied over 1.3 million patients and has been published in over 50 peer reviewed publications.

 
 
Natera San Carlos

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent News

November 19, 2021
Natera's Panorama SMART Study Results Accepted for Publication by the American Journal of Obstetrics and Gynecology (AJOG)
AUSTIN, Texas , Nov. 19, 2021 /PRNewswire/ -- Natera, Inc.  (NASDAQ: NTRA), a leader in personalized genetic testing and diagnostics, announced that the first manuscript from the landmark SMART study has been accepted for publication by the American Journal of Obstetrics and Gynecology (AJOG).
November 11, 2021
Medicare Publishes Final Local Coverage Determination for Pan-Cancer Immunotherapy Monitoring with Natera's Signatera™ MRD Test
Expands Medicare coverage of Signatera beyond its initial indication in early-stage CRC AUSTIN, Texas , Nov. 11, 2021 /PRNewswire/ -- Natera, Inc.  (NASDAQ: NTRA), a leader in personalized genetic testing, today announced that the CMS Molecular Diagnostics Services Program (MolDX) has issued a
November 4, 2021
Natera Reports Third Quarter 2021 Financial Results
AUSTIN, Texas , Nov. 4, 2021 /PRNewswire/ --  Natera, Inc. (NASDAQ:  NTRA), a leader in personalized genetic testing, today reported financial results for the third quarter ended September 30, 2021 and provided an update on recent business progress and financial outlook.
November 3, 2021
Natera Validates Prospera™ With Quantification in Multi-Site, Prospective Trifecta Study
Study represents the largest prospective, fully biopsy-matched cohort of dd-cfDNA for kidney transplant recipients AUSTIN, Texas , Nov. 3, 2021 /PRNewswire/ --  Natera, Inc. (NASDAQ: NTRA), a leader in personalized genetic testing, today announced the initial results 1 from the global, multi-site,
October 28, 2021
Natera Announces Third Quarter 2021 Earnings Conference Call
AUSTIN, Texas , Oct. 28, 2021 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a leader in transforming care through genetic and cell-free DNA testing, today announced that it will release results for its third quarter ended September 30, 2021, after the market close on November 4, 2021.

Upcoming Events

More events are coming soon.

Past events